Elatoside E exhibits significant anti-inflammatory and immunomodulatory activities, making it a compound of interest in the development of therapeutics for chronic inflammatory diseases. It has been studied for its ability to inhibit key pro-inflammatory cytokines such as TNF-α and IL-6, which play central roles in conditions like rheumatoid arthritis and inflammatory bowel disease. Additionally, Elatoside E demonstrates neuroprotective effects in preclinical models, suggesting potential use in treating neurodegenerative disorders such as Alzheimer’s disease. Its capacity to cross the blood-brain barrier enhances its suitability for central nervous system-targeted therapies. Research also indicates antitumor properties, particularly through the induction of apoptosis in certain cancer cell lines, supporting its exploration as an adjuvant in oncology. Due to its natural origin and multi-target activity, Elatoside E is being evaluated for use in functional foods and nutraceuticals aimed at promoting long-term health and preventing age-related diseases.